SCHEMBL272174

SCHEMBL272174

O=CCNC(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18722155 0.78 EPHX1 (0.31)
SCHEMBL10045692 0.77
SCHEMBL14397873 0.75 LDHA (0.40)
SCHEMBL13148688 0.73
SCHEMBL7605311 0.73
SCHEMBL29988 0.73
SCHEMBL29055426 0.73
SCHEMBL12801423 0.73
SCHEMBL868382 0.73
SCHEMBL322841 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 779 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180057506-A1 FUSED DIHYDRO-4H-PYRAZOLO[5,1-C][1,4]OXAZINYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS SUNOVION PHARMACEUTICALS INC. (US) 2018-03-01 US claimed
EP-4735438-A2 HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS Merck Patent GmbH (DE) 2026-05-06 EP disclosed
WO-2025228947-A1 BIFUNCTIONAL COMPOUNDS CAPABLE OF INDUCING DEGRADATION OF POLO-LIKE KINASE1 CROSSFIRE ONCOLOGY B.V. (NL) 2025-11-06 WO disclosed
US-20250179066-A1 ZWITTERIONIC ANTIBACTERIAL COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2025-06-05 US disclosed
EP-4562012-A1 SUBSTITUTED IMIDAZOPYRAZINE COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK3 CELGENE CORPORATION (US) 2025-06-04 EP disclosed
WO-2025106926-A1 CONJUGATES TARGETING FIBROBLAST ACTIVATION PROTEIN AND USES THEREOF Praxis Biotech LLC (US) 2025-05-22 WO disclosed
WO-2025106939-A1 CONJUGATES TARGETING FIBROBLAST ACTIVATION PROTEIN AND USES THEREOF Praxis Biotech LLC (US) 2025-05-22 WO disclosed
WO-2025006783-A2 HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS MERCK PATENT GMBH (DE) 2025-01-02 WO disclosed
US-20240417387-A1 SULFONYLPIPERAZINYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS HOFFMANN-LA ROCHE INC. (US) 2024-12-19 US disclosed
EP-4395828-A1 BIFUNCTIONAL DEGRADERS COMPRISING A TEAD BINDER Novartis AG (CH) 2024-07-10 EP disclosed
WO-2004019000-A2 CHEMICAL REAGENTS AND METHODS FOR DETECTION AND QUANTIFICATION OF PROTEINS IN COMPLEX MIXTURES THE INSTITUTE FOR SYSTEMS BIOLOGY (US) 2004-03-04 WO disclosed
WO-2004009036-A2 COMPOUNDS COMPOSITIONS AND METHODS CYTOKINETICS, INC. (US) 2004-01-29 WO disclosed
WO-2003094918-A1 SUBSTITUTED PIPERAZINE AS MELANOCORTIN RECEPTORS LIGANDS NEUROCRINE BIOSCIENCES, INC. (US) 2003-11-20 WO disclosed
CN-1438996-A Bicyclic cyclohexylamines and their use NMDA receptor antogonists WARNER LAMBERT CO (US) 2003-08-27 CN disclosed
EP-1311488-A1 SUBSTITUTED IMIDAZOLES AS TAFIA INHIBITORS Pfizer Limited (GB) 2003-05-21 EP disclosed
US-6541481-B2 A quinazoline compound PFIZER INC 2003-04-01 US disclosed
CN-1402721-A Novel benzimidazole derivatives as antiproliferative agents PFIZER PROD INC (US) 2003-03-12 CN disclosed
WO-2003002530-A2 PYRROLIDINES AS DIPEPTIDYL PEPTIDASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-01-09 WO disclosed
WO-2002014285-A1 SUBSTITUTED IMIDAZOLES AS TAFIA INHIBITORS PFIZER LIMITED (GB) 2002-02-21 WO disclosed
US-20010034351-A1 Substituted bicyclic derivatives useful as anticancer agents KATH JOHN CHARLES (US) 2001-10-25 US disclosed